Figure 2 | British Journal of Cancer

Figure 2

From: Pharmacological targeting of NF-κB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells

Figure 2

In vivo effect of AS602868 combined with CPT-11 on the development of s.c. HT-29 xenografts. (A–D) Evolution of HT-29 tumour volume. Nude mice received daily oral injections of AS602868, 5 days a week (), and ()/or () CPT-11 i.p. injections twice a week, or vehicle buffer (). Data are the mean±s.d. of tumour measurements using 5 mice/group and are representative of three other experiments. Statistically significant differences between control and AS602868-treated groups on the 6th week and between CPT-11 and CPT-11+AS602868-treated groups on the 10th week are indicated on each figure. NS, not significant.

Back to article page